| 3.06 -0.08 (-2.55%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.57  |
1-year : | 5.22 |
| Resists | First : | 3.91 |
Second : | 4.46 |
| Pivot price | 3.45 |
|||
| Supports | First : | 3.02 | Second : | 2.52 |
| MAs | MA(5) : | 3.2 |
MA(20) : | 3.54 |
| MA(100) : | 4.16 |
MA(250) : | 3.96 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 7  |
D(3) : | 6.3 |
| RSI | RSI(14): 25 |
|||
| 52-week | High : | 5.8 | Low : | 2.42 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ETON ] has closed above bottom band by 3.1%. Bollinger Bands are 0% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.21 - 3.24 | 3.24 - 3.26 |
| Low: | 3 - 3.04 | 3.04 - 3.06 |
| Close: | 3.01 - 3.08 | 3.08 - 3.12 |
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Fri, 19 Apr 2024
Eton Pharmaceuticals cancels stock and warrant sale - Investing.com India
Mon, 15 Apr 2024
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Update - MarketBeat
Fri, 22 Mar 2024
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria - GlobeNewswire
Thu, 14 Mar 2024
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire
Thu, 14 Mar 2024
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Thu, 14 Mar 2024
Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 12.9 (%) |
| Held by Institutions | 27.9 (%) |
| Shares Short | 220 (K) |
| Shares Short P.Month | 227 (K) |
| EPS | -0.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.6 |
| Profit Margin | -3 % |
| Operating Margin | -27.3 % |
| Return on Assets (ttm) | -2.7 % |
| Return on Equity (ttm) | -6.6 % |
| Qtrly Rev. Growth | -13.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.23 |
| EBITDA (p.s.) | -0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 7 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -76.5 |
| PEG Ratio | 0 |
| Price to Book value | 5.09 |
| Price to Sales | 2.48 |
| Price to Cash Flow | 11.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|